Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

Company To Initially Target 70 Cancer Centers

 
• By Alaric DeArment
Form close up, fountain pen and approved stamped on a document. Soft focus.
Blueprint Medicines received FDA approval for Ayvakit in advanced systemic mastocytosis • Source: Shutterstock

More from Business

More from Scrip